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Abstract
Background: L-arginine is the common substrate for the two isoforms of arginase. Arginase I, highly expressed
in the liver and arginase II mainly expressed in the kidney. Arginase I-producing myeloid derived suppressor cells
have been shown to inhibit T-cell function by the depletion of L-arginine. On the other hand, arginase II has been
detected in patients with cancer and is thought to metabolize L-arginine to L-ornithine needed to sustain rapid
tumor growth; however its role in L-arginine depletion is unclear. Thus, in tumor biology, L-arginine metabolism
may play a dual role in tumor growth and in the induction of T cell dysfunction. Therefore, we studied in murine
renal cell carcinoma (RCC) cell lines, the effect of arginase II on tumor cell proliferation and L-arginine depletion.
The effect of arginase inhibitors on cell proliferation was also tested.
Methods: Three murine renal cell carcinoma (mRCC) cell lines were tested for the presence of arginase. nor-
NOHA, an arginase inhibitor was used to substantiate the effect of arginase on cell growth and L-arginine
depletion. Amino acid levels were tested by HPLC.
Results: Our results show that mRCC cell lines express only arginase II and were able to deplete L-arginine from
the medium. Cell growth was independent of the amount of arginase activity expressed by the cells. nor-NOHA
significantly (P = 0.01) reduced arginase II activity and suppressed cell growth in cells exhibiting high arginase
activity.
The depletion of L-arginine by mRCC induced the decrease expression of CD3ζ a key element for T-cell function.
Conclusion: The results of this study show for the first time that arginase II produced by RCC cell lines depletes
L-arginine resulting in decreased expression of CD3ζ. These results indicate that RCC cell lines expressing
arginase II can modulate the L-arginine metabolic pathway to regulate both cell growth and T-cell function.
Blocking arginase may lead to a decrease in RCC cell growth and aid in restoring immune function by increasing
L-arginine availability for T-cell use. Understanding the interplay between arginase II and its interaction with the
immune system may provide future therapeutic benefits to treat patients with RCC.
Published: 25 September 2008
Journal of Hematology & Oncology 2008, 1:14 doi:10.1186/1756-8722-1-14
Received: 29 July 2008
Accepted: 25 September 2008
This article is available from: http://www.jhoonline.org/content/1/1/14
© 2008 Tate et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Hematology & Oncology 2008, 1:14 http://www.jhoonline.org/content/1/1/14
Page 2 of 10
(page number not for citation purposes)
Background
L-arginine is a basic amino acid that plays a central role in
multiple systems including the immune system [1-3]. Two
independent enzymatic pathways, arginase and inducible
nitric oxide synthase (iNOS), regulate L-arginine availa-
bility. L-arginine is metabolized to L-ornithine and urea
by arginase, which is important in the urea cycle and in
the biochemical pathways essential for cell proliferation
[4,5]. Arginase has two isoforms: arginase I, a cytosolic
enzyme found predominantly in hepatocytes, erythro-
cytes, and granulocytes [6-8] and arginase II, found in the
mitochondria of many different tissues, including kidney,
brain, and prostate [6,9,10]. Arginase I, is primarily
involved in the detoxification of ammonia and urea syn-
thesis, whereas arginase II is involved in the synthesis of
L-ornithine, L-proline, and L-glutamate [11].
Several studies have shown that decreased plasma L-
arginine levels and nitric oxide (NO) metabolites induced
by trauma are associated with an increase in arginase I
expression in mononuclear immune cells [12,13], sug-
gesting that L-arginine may have an effect on metabolic
processing in the immune system. In patients with renal
cell carcinoma (RCC), we have demonstrated that argin-
ase I-producing myeloid suppressor cells depletes plasma
L-arginine levels that decreases the expression of T-cell
CD3ζ chain [14]. Arginase II on the other hand, is consti-
tutively expressed in normal kidney [15] and its activity
shown to be increased in breast, colon, and prostate can-
cer [16-18]. This activity may sustain the high demand of
polyamines necessary for tumor growth. Even though, the
depletion of L-arginine has been exclusively attributed to
arginase I [19-21], the potential role of arginase II in L-
arginine depletion has not been taken into detailed con-
sideration. Likewise, the role of arginase II in tumor
growth and in the induction of T-cell dysfunction has not
been determined.
In this study we demonstrate for the first time that only
arginase II is produced by murine renal cell carcinoma
(mRCC) cell lines and that high enzyme levels, specifi-
cally depletes extra cellular L-arginine. This amino acid
deprivation induces the downregulation of CD3ζ expres-
sion in co-cultured Jurkat T-cells. Arginase inhibitors sig-
nificantly suppressed cell growth in cell lines presenting
high arginase II activity.
Methods
Tissue culture medium
Complete tissue culture medium consisted of RPMI-1640
containing 1,140 μM L-arginine and supplemented with
10% fetal calf serum (Hyclone, Logan, UT), 25 mM
HEPES, 4 mM L-glutamine, and 100 units/mL penicillin/
streptomycin, 1 mM non-essential amino acids, and 1
mM sodium pyruvate. All other reagents were purchased
from Lonza Walkersville Inc., Walkersville, MD.
Cell culture
For this study we used mRCC cell lines SIRCC-1.2 (CL-2)
and SIRCC 1.19 (CL-19), both of which are sub-clones
derived from a streptozotocin-induced kidney tumor [22]
and Renca. All of the cell lines were kindly provided by Dr.
Robert H. Wiltrout (NCI). Cells were cultured at 37°C in
complete media and subcultured every 3 days. Experi-
ments were prepared by plating 300,000 cells in six-well
plates and allowed to attach for 24 hours. Media was
changed (Time 0) to perform all of the experiments. The
cells were harvested at 24, 48, and 72 hours using 0.5%
Trypsin/EDTA (Sigma, St. Louis, MO) and lysed with a Tri-
ton-based buffer [23] to obtain cytoplasmic extracts to test
immediately for arginase activity. Protein concentration
was determined by the BCA (bicinchoninic acid) protein
assay kit (Pierce Biotechnology Inc., Rockford, IL). Lysates
were stored at -70°C until used for Western blots.
Arginase activity
Freshly prepared cytoplasmic extracts from cultured
mRCC cells were tested for arginase activity by the conver-
sion of L-arginine to L-ornithine (nanomoles/106cells/
hr), as described elsewhere [24].
Western blot
Twenty-five micrograms of cytoplasmic extract were elec-
trophoresed in 14% Tris-glycine gels (Invitrogen,
Carlsbad, CA) and transferred to polyvinylidiene difluo-
ride (PVDF) membranes (Invitrogen). Immunoblotting
were performed with antibodies for arginase I or arginase
II (1:200, Santa Cruz Biotech, Santa Cruz, CA). Detection
was achieved by horseradish peroxidase-conjugated anti-
bodies (1:3000, Santa Cruz) and an enhanced chemilumi-
nescent kit (ECL, GE Healthcare, Piscataway, NJ). Arginase
protein levels were visualized on X-OMAT AR films
(Kodak, Rochester, NY).
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA from 1 × 106 cells were extracted using TRIzol
(Invitrogen), treated with DNase I (Invitrogen), and
reverse transcribed using Superscript II (Invitrogen). PCR
amplification was done using primers for mouse arginase
I, arginase II, and β-actin as follow: Arginase I forward 5'-
CAG AAG AAT GGA AGA GTC AG-3', reverse 5'-CAG ATA
TGC AGG GAG TCA CC-3', Arginase II forward 5'-TGA
TTG GCA AAA GGC AGA GG-3', reverse 5'-CTA GGA GTA
GGA AGG TGG TC-3', and β-actin forward 5'-CCA GAG
CAA GAG AGG TAT CC-3', reverse 5'-CTG TGG TGG TGA
AGC TGT AG-3'. The expected sizes of amplified frag-
ments were arginase I, 250 bp; arginase II, 310 bp; and β-
actin, 436 bp. PCR products were visualized in ethidium
bromide agarose gels.Journal of Hematology & Oncology 2008, 1:14 http://www.jhoonline.org/content/1/1/14
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Amino acid detection
High performance liquid chromatography (HPLC) was
conducted on deproteinized supernatants labeled with O-
phtaldialdehyde (OPA). Analytes were eluted with 100
mM sodium acetate buffer, pH 5.0, with a linear gradient
consisting of methanol (80%) and acetonitrile (80%).
The analytes in the sample were calculated on the basis of
standard curves of known amounts.
Proliferation assays
Cells (1 × 104/well/1 mL) were plated in 24-well plates
and allowed to adhere for 24 hours. The cells were treated
with different concentrations of Nω-Hydroxy-nor-L-
arginine (nor-NOHA), 0.5 mM, 1 mM, and 2 mM to
determine the optimal conditions to suppress cell growth,
or cultured without the inhibitor to be used as controls.
The cultures were pulsed once with [3H]-thymidine (1.0
μCi, Perkin Elmer Life Sciences, Boston, MA) and tested
for [3H] incorporation at 24, 48, and 72 hours using a
TOPCOUNT Microplate Scintillation Counter (Packard,
Meridien, CT). Cell viability was checked by trypan blue
exclusion at each time point. Each condition was tested in
triplicate.
Expression of CD3ζ by co-cultured Jurkat T-cells
To determine the effect of L-arginine deprivation on the
expression of CD3ζ, mRCC cell lines (600,000 cells/well)
were cultured in six-well plates with 5 mL of complete
media for 24 hours. 5 × 105 Jurkat T-cells (ATCC, Manas-
sas, VA) were then added to the upper chamber of a trans-
well system (Falcon-BD, San Jose, CA) and co-cultured for
24, 48, and 72 hours. CD3ζ expression was determined by
flow cytometry as described elsewhere [25]. Jurkat cells
cultured in complete media were used as controls. L-
arginine levels were determined in the supernatants by
HPLC.
Statistical analysis
Statistical analysis was calculated by Student's t-test using
the Graph Pad Prism 3.0 statistical program (GraphPad
Software Inc., San Diego, CA). P < 0.05 was taken to indi-
cate statistical significance.
Results
Arginase expression in mRCC cell lines
First, we investigated the enzymatic activity of arginase in
the mRCC cell lines CL-2, CL-19, and Renca. CL-19 cell
line had the highest arginase activity, which was 3.0-fold
greater than the Renca and 9.8-fold greater than the CL-2
cell line (Figure 1A). Using specific antibodies for arginase
I and arginase II, we found that the cell lines only
expressed detectable levels of arginase II, and not arginase
I (Figure 1B). By RT-PCR, we observed arginase II gene
expression in all 3 of the mRCC cell lines, but not arginase
I gene expression (Figure 1C). Arginase II mRNA expres-
sion was greatest in CL-19 compared to Renca and CL-2
cell lines. The data show a direct association amongst argi-
nase II mRNA expression, protein expression, and enzy-
matic activity.
Arginase II produced by the CL-19 cell line depletes extra 
cellular L-arginine
The effect of arginase II on L-arginine, L-ornithine, and L-
glutamine content in the conditioned culture medium
was assessed by HPLC. The CL-19 cell line, which
expressed high levels of arginase II, depleted the media L-
arginine concentration by about 50% at 24 hours (P =
0.005, Figure 2A) and about 90% at 48 and 72 hours (P <
0.001) when compared to media controls. L-arginine lev-
els remained unchanged in CL-2 and Renca cultures
throughout the experimental time points. Concomitantly,
there was a significant increase in L-ornithine production
by CL-19 after 48 and 72 hours (P = 0.001 and P < 0.0001)
compared to CL-2 and Renca cell lines in which the levels
did not change significantly at any time point (Figure 2B).
All cell lines also depleted the culture supernatants of L-
glutamine at the same rate during the first 24 hours. How-
ever, at 72 hours, the depletion of L-glutamine was signif-
icantly higher in CL-2 and Renca (P  = 0.001 and P  =
0.016) than in CL-19 (Figure 2C).
Role of arginase II and effect of nor-NOHA on mRCC cell 
proliferation
We assessed whether arginase II could play a role in the
proliferation of the three different mRCC cell lines. The
cell lines were cultured for 24 hours and the media
replaced with 0.5, 1 and 2 mM of nor-NOHA, pulsed once
with [3H]-thymidine and tested for [3H] incorporation
after 24, 48, and 72 hours in culture. At 72 hours in cul-
ture a concentration of 2 mM nor-NOHA was able to sig-
nificantly suppress cell growth in the high arginase
producer CL-19 cell line. No significant effect on cell
growth suppression was observed with the lower concen-
trations of nor-NOHA (data not shown). Therefore, we
used 2 mM nor-NOHA for the rest of the experiments.
When the 3 cell lines were cultured in presence of 2 mM
nor-NOHA, they incorporated [3H]-thymidine at the
same rate during the first 48 hours. However at 72 hours,
significant differences in cell proliferation among the
lines were apparent. CL-2 proliferation was significantly
lower (P = 0.003) compared to CL-19, which presented
the highest arginase activity. Interestingly, the Renca cell
line, which had intermediate arginase activity, had the
highest proliferation rate compared to the CL-19 (P  =
0.01) and CL-2 (P = 0.003) cell lines (Figure 3A). The
higher L-glutamine consumption observed in Renca cells
(Figure 3C) suggested that this line may utilize a different
pathway for its cellular growth, bypassing arginase for the
production of L-ornithine.Journal of Hematology & Oncology 2008, 1:14 http://www.jhoonline.org/content/1/1/14
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Arginase II expression in mRCC cell lines Figure 1
Arginase II expression in mRCC cell lines. (A) After 48 hours in culture, CL-19 cells presented significantly more arginase 
activity (*P < 0.0001) than did either CL-2 or Renca cells. Similar results were found after 72 hours in culture. (B) Twenty five 
micrograms of protein were tested for arginase I and arginase II expression by Western blot analysis. Normal mouse liver and 
kidney were used as positive controls for arginase I and arginase II respectively, whereas GAPDH was used as house keeping 
protein. (C) Total RNA from CL-2, CL-19 and Renca cells were obtained by TRIzol extraction and 1 μg of RNA was tested for 
arginase I, arginase II, and β-actin by RT-PCR. DNA fragment sizes generated by RT-PCR: arginase I, 250 bp; arginase II, 310 bp; 
and β-actin, 436 bp. These data are from a single experiment that is representative of five separate experiments.Journal of Hematology & Oncology 2008, 1:14 http://www.jhoonline.org/content/1/1/14
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We then tested the effect of the arginase inhibition by nor-
NOHA (2 mM) on cell proliferation at 24, 48, and 72
hours. Growth of CL-19, which had the highest level of
arginase II activity, was significantly inhibited (P = 0.017,
Figure 3B). In contrast, nor-NOHA had no significant
effects on the growth rates of the low arginase producer
cell lines CL-2 (P = 0.14) and Renca (P = 0.07). Cell via-
bility of the cells was > 95% at the different points and
conditions of the experiments.
nor-NOHA blocks arginase activity and L-arginine 
consumption in CL-19 cell line
Since nor-NOHA significantly inhibited cell proliferation
of CL-19, we wanted to test the effect of this inhibitor on
arginase activity and L-ornithine production. Arginase
activity increased in this cell line over the time of the
experiments. When 2 mM of nor-NOHA was added to the
cultures, significant reduction in arginase activity occurred
at 48 and 72 hours (P = 0.002 and P = 0.001 respectively)
(Figure 4A). Importantly, independent of the amount of
arginase produced by this cell line, the effect of arginase
inhibition by nor-NOHA was similar at all time points
tested. The inhibition of arginase activity in CL-19 by nor-
NOHA significantly blocked (P = 0.0001) the depletion of
L-arginine as well as the accumulation of L-ornithine (P <
0.0001) after 48 hours compared to CL-19 cultures with-
out the inhibitor (Figure 4B). We did not observe signifi-
cant changes in arginase inhibition, L-arginine depletion
and L-ornithine production when nor-NOHA was added
to cultures with CL-2 and Renca cells (data not shown).
L-arginine depletion by arginase II induces CD3ζ 
downregulation in Jurkat T-cells
Jurkat T-cells rapidly lose CD3ζ in absence of L-arginine.
Therefore, we tested if L-arginine depletion by mRCC argi-
nase II had any effect on CD3ζ expression in trans-wells
co-cultured Jurkat T-cells. At 24 hours in co-culture with
any of the mRCC cell lines, Jurkat T-cells did not show any
significant reduction on CD3ζ expression. However, after
48 hours Jurkat T-cells co-cultured with CL-19 had a dra-
matic decrease in the expression of CD3ζ as compared to
Jurkat controls (MFI: 16.9 and 48.5 respectively, Figure 5).
The decreased expression of CD3ζ in Jurkat T-cells paral-
leled the significant depletion of L-arginine (P = 0.03) in
the co-cultured CL-19 compared to the Jurkat control (Fig-
ure 5 lower panel). In contrast, the expression of CD3ζ in
Jurkat T-cells co-cultured with CL-2 or Renca was similar
to that expressed in the Jurkat control, where the levels of
L-arginine remained unchanged (Figure 5).
Discussion
Our major objective was to assess whether arginase II was
able to deplete L-arginine from the tissue culture superna-
tants of murine renal cell carcinoma cell lines and deter-
mine their effect on cell proliferation. In adult mammals,
the majority of endogenous L-arginine is synthesized
from citrulline in the kidney and released to systemic cir-
culation where it is catabolized by arginase I or arginase II
[4,11]. Therefore, the study of the L-arginine metabolic
L-arginine, L-ornithine and L-glutamine levels Figure 2
L-arginine, L-ornithine and L-glutamine levels. Tissue 
culture supernatants from CL-2, CL-19, and Renca cells were 
collected at 24, 48, and 72 hours. They were analyzed by 
HPLC after deproteinization with methanol and derivatiza-
tion with OPA for (A) L-arginine and (B) L-ornithine and (C) 
L-glutamine. Standards of L-arginine, L-ornithine and L-
glutamine in methanol were run with each experiment. 
Results are expressed as means ± SE of duplicate determina-
tions from four independent experiments. (* P = 0.005. ** P 
< 0.0001 significant differences for CL-19 compared to the 
other cell lines).Journal of Hematology & Oncology 2008, 1:14 http://www.jhoonline.org/content/1/1/14
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pathway in mRCC cell lines provide us with a good model
to better understand the biology of renal carcinoma.
Western blot and RT-PCR analyses confirmed that argin-
ase activity from mRCC cell lines was attributable solely to
arginase II and not to arginase I. This is an important find-
ing, since most studies have demonstrated that only argi-
nase I produced by tumor cells, macrophages, smooth
muscle and endothelial cells [26-29] is capable of deplet-
ing L-arginine which results in the induction of T-cell dys-
function [19,30]. The role of arginase II on L-arginine
metabolism in disease and cancer has been quite underes-
timated, especially taking into account its wide tissue dis-
tribution and its role in polyamine production. Previous
studies have shown that the expression of either arginase
I or arginase II plays a key role in polyamine synthesis and
cell proliferation [31]. Although the three cell lines used
in this study were all derived from kidney tumors, they
had very different arginase II activities. CL-2 and CL-19,
both derived from renal tumors induced by streptozo-
tocin, had low and high arginase II activities, respectively.
The Renca cell line, derived from a spontaneous renal
tumor had intermediate activity. These three lines provide
us with an ideal model to study the biology of RCC with
regard to L-arginine consumption, L-ornithine produc-
tion, and cell proliferation. We demonstrate for the first
time that arginase II produced by the high arginase RCC
cell line CL-19 dramatically depletes L-arginine from the
tissue culture supernatants at 48 hours with a concomi-
tant increase in L-ornithine production.
In contrast, the cell lines CL-2 and Renca, both of which
expressed low levels of arginase II compared to CL-19 did
not deplete L-arginine significantly; nor did they increase
the levels of L-ornithine sufficiently to promote growth.
Instead, we observed that CL-2 and Renca cells utilize L-
glutamine at higher rates than CL-19, suggesting that this
could be a possible mechanism used by these cells to con-
vert L-glutamine to glutamate, bypassing arginase for the
production of L-ornithine as described previously in
murine macrophages and human monocytes [32]. It is
likely that CL-2 and Renca cells do not need arginase to
make L-ornithine because they utilize L-glutamine to pro-
duce the necessary amount of L-ornithine needed for their
cell growth. This observation indicates that arginase II is
important for CL-19 growth but not for CL-2 and Renca
cells due to the positive effect of nor-NOHA in suppress-
ing cell growth in CL-19. We used nor-NOHA in our
experiments because it has been demonstrated that nor-
NOHA is a potent and selective inhibitor of arginase [33]
in contrast to NOHA which is a key intermediate product
in the biosynthesis of nitric oxide by L-arginine. We were
expecting to have a greater arginase inhibition by nor-
NOHA in our cultures similar to those observed when
NOHA was used to inhibit cell proliferation in cell lines
from breast, colon, prostate and endothelial cells as previ-
ously reported [16,17,34,35]. This may be due to the fact
that these cell lines can use L-arginine to synthesize
NOHA from arginase, then increasing its inhibitory effect.
In contrast, it is also possible the growth of renal cell car-
cinoma cells is arginase II independent resulting in the
low inhibitory effect of nor-NOHA.
Effect of arginase inhibitor nor-NOHA on cell proliferation Figure 3
Effect of arginase inhibitor nor-NOHA on cell proliferation. (A) Proliferation of CL-2, CL-19 and Renca cells was 
assessed by [3H]-thymidine incorporation at 24, 48, and 72 hours in culture. At 72 hours, the growth rates for CL-19 and 
Renca cells were significantly greater than CL-2 (* P = 0.009 and ** P = 0.003 respectively). (B) nor-NOHA (2 mM) and [3H]-
thymidine were added at the same time and cell proliferation was determined at 24, 48, and 72 hrs. Cultured cells without the 
inhibitor were used as controls. Only CL-19 proliferation was significantly inhibited (* P = 0.010) compared to the untreated 
control cells. Results are expressed as CPM means ± SE of triplicate determinations from five independent experiments.Journal of Hematology & Oncology 2008, 1:14 http://www.jhoonline.org/content/1/1/14
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At 48 hours in culture, CL-19 cells significantly depleted
L-arginine from the culture supernatant; however, these
cells continued growing at the same rate up to 120 hours
in the absence of the amino acid (data not shown). L-
arginine deprivation should promote the death of CL-19
cells, as reported previously to occur in other cancer cells
lines [36,37], indicating that these cells are more adept at
circumventing L-arginine deficiency by increasing the
recycling efficiency from L-ornithine to citrulline to con-
vert L-arginine fast enough to sustain relatively normal
tumor cell growth rate as previously shown [38]. Since
RCC cells have a strong dependence for L-arginine [39],
our laboratory is currently studying whether or not these
cells are utilizing L-glutamine or citrulline as the source
for L-arginine synthesis.
L-arginine is a non-essential amino acid that plays a cen-
tral role in several biological systems including the
immune response. Paradoxically, L-arginine deprivation
can cause tumor cell death as well as T-cell dysfunction.
The loss of CD3ζ is the only arginase-triggered mecha-
nism described so far that has proven to have direct rele-
vance to T-cell function [40,41]. It has been previously
shown that Jurkat T-cells cultured in medium lacking L-
arginine showed decreased expression of CD3ζ and
decreased cell proliferation [42]. Similar results were
obtained when stimulated normal human T-cell lym-
phocytes were cultured in the absence of L-arginine [25].
In the current experiments, we found that after 48 hours
in culture, depletion of L-arginine by CL-19 arginase II
activity caused the decreased expression of CD3ζ in co-
cultured Jurkat T-cells. Therefore, L-arginine availability
can regulate the expression of CD3ζ, an essential compo-
nent in T-lymphocyte signal transduction and function. L-
arginine levels in the serum of normal individuals ranges
from 115 μM to 210 μM [4]. Our data show that at 48
hours, the levels of L-arginine in the trans-well tissue cul-
ture supernatant was 100 μM, a concentration sufficient to
induce a decrease in CD3ζ expression.
Most tumor cells have a great demand for amino acids to
support rapid proliferation and L-arginine is the first
amino acid depleted faster than other nutrients by normal
cell metabolism. Therefore, L-arginine could be a reason-
able target of deprivation strategy for the type of tumors
with a low recycling efficiency. Taken collectively, these
findings, demonstrate that the availability of L-arginine
and L-ornithine could be the limiting factor to control cell
proliferation. We believe that treating RCC cells down-
stream from the L-arginine metabolic pathway by block-
ing polyamine production will have a major impact in
suppressing tumor growth. This is supported by the use of
DL-α-difluoromethylornithine, which completely blocks
the proliferation of these cell lines independent of the
presence of L-arginine, L-ornithine and arginase in addi-
tion to the promising anti-tumor effect in human tumors
[43-45].
Renal cell carcinoma is a malignancy with poor prognosis
due to its strong resistance to conventional cancer treat-
ments and frequent metastases. With the standard immu-
notherapeutic treatment of IL-2 and IFNα for RCC, only
10–20% of the patients respond [46]. This lack of
response may be caused by the markedly impaired T-cell
function associated with a decreased expression of the
CD3ζ receptor. Therefore, it is still desirable to find better
approaches to treat RCC. Modulating the L-arginine met-
abolic pathway by breaking down this amino acid
Effect of nor-NOHA on arginase activity and amino acid lev- els Figure 4
Effect of nor-NOHA on arginase activity and amino 
acid levels. (A) Significant arginase inhibition was observed 
in cell lysates of CL-19 cultures treated with nor-NOHA (2 
mM) after 48 (*P = 0.002) and 72 hours (** P = 0.001) as 
compared to untreated cells. (B) Effect of nor-NOHA in 
inhibiting both L-arginine (μM) depletion (*P = 0.001) and L-
ornithine (μM) production (**P < 0.0001) in the supernatants 
of CL-19 cultures, as compared to CL-19 untreated cultures. 
Results are expressed as means ± SE of duplicate determina-
tions from four independent experiments.Journal of Hematology & Oncology 2008, 1:14 http://www.jhoonline.org/content/1/1/14
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required for tumor cell growth could be a novel approach
to control it. The study of the mechanisms by which argi-
nase II activity and L-arginine depletion affect tumor
growth will help better understand the biology of RCC
and its interaction with the immune system. The results of
these studies may provide future therapeutic benefits.
Conclusion
Arginase II produced by renal cell carcinoma cells can
modulate L-arginine levels to regulate both cell growth
and T cell function. Blocking arginase may lead to a
decrease in RCC cell growth and aid in restoring immune
function by blocking the formation of polyamines, thus
providing a novel therapeutic advance.
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